Intellipharmaceutics International Inc. J (T:I)
Business Focus: N/A
Feb 02, 2017 05:00 pm ET
Intellipharmaceutics Announces FDA Acceptance for Filing of NDA for Rexista™ (oxycodone hydrochloride extended release), an Abuse Deterrent Opioid Analgesic for the Treatment of Moderate to Severe Pai
TORONTO, Feb. 02, 2017 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the U.S. Food and Drug Administration ("FDA") has accepted for filing the Company’s previously-announced New Drug Application ("NDA") seeking authorization to market its RexistaTM abuse-deterrent oxycodone hydrochloride extended release tablets in the 10 mg,...
Oct 14, 2016 09:00 am ET
Intellipharmaceutics to Present at Dawson James Securities Growth Stock Conference
TORONTO, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Dawson James Securities Growth Stock Conference on October 20, 2016. Domenic Della Penna, Chief Financial Officer, will be presenting at 11:15 A.M. (EDT) in the Wyndham Grand Hotel in Jupiter, Florida....
Oct 13, 2016 11:00 pm ET
Intellipharmaceutics Announces Third Quarter 2016 Results
TORONTO, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and nine months ended August 31, 2016. All dollar amounts referenced herein are in United States dollars unless otherwise noted....
Oct 11, 2016 04:46 pm ET
Intellipharmaceutics Signs an Exclusive License and Commercial Supply Agreement with Mallinckrodt
TORONTO, Oct. 11, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has entered into a license and commercial supply agreement with Mallinckrodt LLC ("Mallinckrodt"), by which the Company has granted Mallinckrodt an exclusive license to market, sell and distribute in the United States the following extended release drug p...
Oct 11, 2016 09:28 am ET
IIROC Trade Resumption - I
TORONTO, Oct. 11, 2016 /CNW/ - Trading resumes in:
Oct 07, 2016 06:35 pm ET
Intellipharmaceutics Announces FDA Tentative Approval for Generic Seroquel XR®
TORONTO, Oct. 07, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that the Company today received tentative approval from the U.S. Food and Drug Administration ("FDA") for the Company's abbreviated new drug application ("ANDA") for quetiapine fumarate extended-release tablets in the 50, 150, 200, 300 and 400 mg strengths. The Comp...
Oct 07, 2016 04:56 pm ET
IIROC Trading Halt - I
TORONTO, Oct. 7, 2016 /CNW/ - The following issues have been halted by IIROC:
Sep 22, 2016 05:18 pm ET
IIROC Trade Resumption - I
TORONTO, Sept. 22, 2016 /CNW/ - Trading resumes in:
Sep 22, 2016 04:06 pm ET
IIROC Trading Halt - I
TORONTO, Sept. 22, 2016 /CNW/ - The following issues have been halted by IIROC:
Sep 22, 2016 04:05 pm ET
Intellipharmaceutics Responds to Recent Trading Activity
TORONTO, Sept. 22, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, at the request of Investment Industry Regulatory Organization of Canada (“IIROC”) on behalf of the Toronto Stock Exchange, confirms that as of the date of this news release, they are not aware of any corporate developments that would cause the recent movement in the Company's s...
Aug 25, 2016 04:00 pm ET
Intellipharmaceutics to Present at the 18th Annual Rodman & Renshaw Global Investment Conference
TORONTO, Aug. 25, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the 18th Annual Rodman & Renshaw Global Investment Conference on September 13, 2016. Domenic Della Penna, Chief Financial Officer, will be presenting at 2:10 P.M. (Eastern Time) in the Lotte New York Palace Hotel i...
Jul 13, 2016 08:00 am ET
Intellipharmaceutics Announces Second Quarter 2016 Results
TORONTO, July 13, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three and six months ended May 31, 2016. All dollar amounts referenced herein are in United States dollars unless otherwise noted....
Jul 05, 2016 07:30 am ET
Intellipharmaceutics Reports Update on Rexista™ XR: FDA Grants Waiver of NDA Filing Fee, and Topline Pharmacokinetics Results Indicate No Food Effect
TORONTO, July 05, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) (“Intellipharmaceutics” or the “Company”), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today provided an update on its RexistaTM XR (oxycodone hydrochloride extended release tablets) new drug application (“NDA”) candidate....
Jun 06, 2016 05:30 pm ET
Intellipharmaceutics Closes Public Offering for US$5.2 Million
TORONTO, June 06, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today the closing of its previously announced underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, for gross proceeds of approximately US$5.2 million. The Company sold units comprised of an aggregate of 3,229,814 common shares and warrants to purchase...
May 27, 2016 10:45 am ET
IIROC Trade Resumption - I
TORONTO, May 27, 2016 /CNW/ - Trading resumes in:
May 27, 2016 10:30 am ET
IIROC Trading Halt - I
TORONTO, May 27, 2016 /CNW/ - The following issues have been halted by IIROC:
May 27, 2016 09:29 am ET
Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
TORONTO, May 27, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, equal to the closing price of the Company’s shares on the NASDAQ on May 26, 2016. In connection with the offering, the Company will be issuing an aggregate of 3,229,814 common ...
May 26, 2016 05:24 pm ET
Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
TORONTO, May 26, 2016 (GLOBE NEWSWIRE) -- Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Dawson James Securities, Inc. is acting as sole bookrunner for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be ...
May 12, 2016 09:00 am ET
Intellipharmaceuticals International's CFO Domenic Della Penna Interviewed by The Life Sciences Report
Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Canadianinsider.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Read more...Insider information is based on filings made on the System
for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission.Read less
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Interactive technical study charts by TradingView. Copyright © 2024 INK Research Corp. All rights reserved. All trade-marks or trade names not owned by INK Research Corp. are the property of their respective owners.